Our Pipeline

Pan-Amyloid Removal & Reversal Of The Underlying Pathology Of Systemic Amyloidosis

Making New Solutions Possible for Patients


Using our proprietary pan-amyloid removal (PAR) technology, we are advancing a pipeline of novel therapeutics that remove toxic, disease-causing amyloid throughout the body with high specificity, and the potential to reverse disease pathology. We are pioneering first-in-class novel pan-amyloid therapies that bind to all types of amyloid, so that our therapies can be used for patients with all types of systemic amyloidosis and at all stages of disease.

Why It Matters

There is a critical unmet need for disease modifying therapies that can remove amyloid across all stages and types of systemic amyloidosis. The existing approved drugs for amyloidosis do not address the toxic amyloid deposits that are present and accumulate in organs and are the cause of disease burden, progressive organ failure and increased mortality in patients.

Our Pioneering Pan-Amyloid Pipeline

Attralus Novel Pan-Amyloid Targeting Pipeline updated Mar 2024

(1) In addition to AT-02, our pipeline of Systemic Amyloidosis therapeutics includes AT-06, a preclinical candidate that incorporates the PAR-peptide into a chimeric antigen receptor expressed in macrophages or monocytes (CAR-M), which is an alternative approach to enabling the immune system to remove amyloid deposits.

Our Pan-Amyloid Removal (PAR) Therapeutics

With the aim to treat all types of patients with systemic amyloidosis and open the door to reversing disease, at Attralus we are advancing our pipeline of product candidates for pan-amyloid removal. We have designed our novel biologics to achieve pan-amyloid removal with superior amyloid binding and immune-mediated phagocytosis.

AT-02: Pan-Amyloid Reactive Peptide-mAb Fusion Designed for Strong Binding and Phagocytosis (PAR-Peptide Technology)


PAR-Peptide + IgG1 Antibody
AT-02 is the company’s lead pan-amyloid removal (PAR) therapeutic candidate for systemic amyloidosis. AT-02 is a humanized IgG1 monoclonal antibody genetically fused with the company’s proprietary pan-amyloid binding peptide, enabling binding to multiple types of amyloid deposits. The Fc region of the antibody stimulates the immune system to remove amyloid deposits that are bound by AT-02. AT-02 uses a similar pan-amyloid peptide to 124I-evuzamitide, the company’s diagnostic agent, which has been shown in multiple clinical trials to selectively bind to amyloid deposits in the heart, liver, kidney, and other organs in multiple types of amyloidosis. As a result, the company expects AT-02 to bind specifically to amyloid in systemic amyloidosis patients. Preclinical data have shown the ability of AT-02 to bind to multiple amyloid types in major organs, induce macrophage mediated phagocytosis, and remove amyloid. AT-02 is currently being evaluated in an open label phase 1 / 2 clinical trial in ATTR and AL amyloidosis patients.
AT-06 peptide CAR-M fusion


PAR-Peptide + CAR-M

We have an additional therapeutic candidate that incorporates differentiated technology to treat all types of systemic amyloidosis. Our preclinical therapeutic candidate AT-06 incorporates the PAR-peptide into a chimeric antigen receptor expressed in monocytes (CAR-M), which is an alternative approach to enabling the immune system to remove amyloid deposits.

Our Amyloid-Specific Imaging Agents

In support of our therapeutic strategy, we are also developing the world’s first amyloid-specific imaging agent which will improve the clinical journey for patients and dramatically expand the population of those who are diagnosed.

AT-01 Iodine (I-124) evuzamitideDiagnostic Imaging agent for systemic amyloidosis

Iodine (I-124) evuzamitide

PAR-Peptide + I-124

124I-evuzamitide (iodine-124 evuzamitide) utilizes the company’s pan-amyloid binding peptide as an amyloid-specific imaging agent to image all types of systemic amyloidosis by PET/CT imaging. In clinical trials, 124I-evuzamitide has been shown to detect multiple types of amyloid deposits, including AL and ATTR, in major organs such as the heart, kidney, liver, and spleen. Attralus has a special protocol assessment (SPA) in place with the FDA to conduct a single pivotal Phase 3 trial for 124I-evuzamitide.

AT-06 Diagnostic Imaging agent for systemic amyloidosis


PAR-Peptide + 99m Tc
AT-05, uses the same pan amyloid binding peptide as 124I-evuzamitide but is labelled with technetium-99m (Tc-99m, 99mTc). AT-05 is designed to be used with single-photon emission computerized tomography (SPECT) to be more accessible to community cardiologists, and thereby support broader screening in addition to diagnosis. AT-05 is currently in a Phase 1 clinical trial.

Our Neurodegenerative Program

Attralus is developing the next generation of therapies for neurodegenerative diseases by simultaneously targeting multiple proteinopathies. Patients suffering from neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Lewy Body diseases, often have multiple proteinopathies. The company’s research is aiming to capitalize on this by binding to multiple misfolded protein aggregates including Aβ, Tau, and α-Synuclein. Attralus’ pan-amyloid product candidates provide an opportunity for therapeutics that can simultaneously target multiple proteinopathies in individual patients unlike approved therapies that target a single proteinopathy. The company is also exploring a blood brain barrier shuttle to potentially improve brain penetration.